Lupin gets FDA approval for generic Triamcinolone Acetonide Ointment USP, 0.1%
Deepthi | Myequity news | Date : 22-10-2018 15:25:00 IST
Pharma major Lupin announced that it has received approval for its Triamcinolone Acetonide Ointment USP, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Mylan Pharmaceuticals, Inc.’s (Mylan) Triamcinolone Acetonide Ointment, 0.1%.
Lupin’s Triamcinolone Acetonide Ointment USP, 0.1% is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses.
Triamcinolone Acetonide Ointment USP, 0.1% had annual sales of approximately USD 25.7 million in the US (IQVIA MAT June 2018).
About Lupin Limited:
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded &generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.